Sections of human anterior optic nerve and nerve head were incubated in a physiological solution containing a radiolabelled beta blocker at a low concentration. Tbe beta blocker used was (-)-e25iodo )-cyanopindolol, which has a higb affinity and specificity for beta-adrenergic receptors. Concurrent incubations were performed with a great excess of unlabelled beta blocker added to demon strate non-specific binding. Following incubation the sec tions were washed and dried. Tbey were then apposed to photographic film for 5 days and developed. Incubations were performed witb the stereoisomers of propranolol and an alpha blocker as well as specific beta-one and beta-two blockers. Beta-adrenergic receptors were demonstrated in anterior optic nerve and optic nerve head. The majority were of the beta-two subtype.
The main group of drugs used in the medical treatment of glaucoma is the topical beta blockers. It is known that they reduce aqueous production, I probably by the inhibition of beta-adrenergic receptors in the ciliary body. They are known to have an effect elsewhere in the body, notably the heare and chest. 3, 4 It is possible that they may act on other ocular structures either by direct diffusion through the aqueous or via the ocular circulation.
Beta receptors have been identified in the ciliary body in humans5 and animals. 6 They have also been identified in the trabecular meshwork/ cornea, 8 extraocular muscles,9 retina,6 retinal vesselsIO,II and choroid. 1 2 They have not so far been identified in anterior optic nerve or nerve head. It has been suggested that reduced perfusion of the optic nerve head leads to optic disc cupping and visual field loss in glaucoma. 13 Beta receptors mediate dilatation of vas cular smooth muscle elsewhere in the body.14 Information regarding the presence and nature of beta receptors in anterior optic nerve and particularly the optic nerve head is therefore desirable. Eye (1993)7, 122-126
Beta receptors have been divided into beta-one and beta-two subgroups according to a slight difference in the response of various target organs to different pharmac ological agents.I5 The majority of beta receptors already identified in the eye are of the beta-two SUbtype. Those in the chest, whch mediate dilatation of bronchiolar smooth muscle, are of the beta-two subtype, as are those on vas cular smooth muscle.I4 The bronchospasm induced by non-selective topical beta blockers in susceptible patients is due to inhibition of these. Betaxolol is a beta blocker which is highly selective for beta-one receptors. When administered topically it lowers intraocular pressureI6 but has less effect on pulmonary function than a non-selective beta blocker.I7 If beta receptors are present in anterior optic nerve information about their type is also desirable as a selective beta blocker may have a different effect on the beta receptors to a non-selective beta blocker.
In this study we attempted to demonstrate and charac terise beta-adrenergic receptors in sections of human anterior optic nerve with an in vitro autoradiographic tech nique which has been used before to demonstrate beta receptors elsewhere in the eye. 6 The radioligand used was (-)-C 2 5iodo )-cyanopindolol (ICYP), which has previously been demonstrated to have a very high affinity and speci ficity for beta-adrenergic receptors. 1 8
METHODS
Human anterior optic nerve and nerve head were removed within 16 hours of death from donor eyes with no history of ocular disease. The structures were mounted in Tissue Tek and snap frozen in isopentane cooled in liquid nitro gen at -80°C. They were stored at the same temperature. Sections 8 f..l m thick were cut on a cryostat at -20°C (Bright Instruments, Huntingdon, UK) and mounted on gelatine-coated glass slides. The slides were then brought to room temperature and placed in an incubation medium comprising 150 mmol/l sodium chloride, 50 mmol/l Tris HCI buffer at pH 7.5, 10 mmol/l magnesium chloride, 1 mmol/l ascorbic acid and 10 f..l mol/l phenylmethylsul phonylftuoride to which ICYP had been added. Between 20 and 50 pmol/l ICYP was used. After 45 minutes of incubation the slides were washed in distilled water for 20 seconds followed by three washes of 10 minutes each in ice-cold buffer. They were then washed for a further 20 seconds in distilled water. The slides were then dried in a stream of cold air and apposed to Hyperfilm 3H (Amer sham, UK) in light-tight cassettes for 5 days. The film was . developed in D19 (Kodak, UK) for 4 minutes, fixed in Unifix (Kodak, UK) for 4 minutes, washed in cold running water and dried.
Non-specific binding was determined by incubating adjacent sections in separate buffer which contained 10 Ilmol/l unlabelled propranolol in addition to ICYP. Further incubations were performed with similar sections and concentrations of ICYP but with a variety of unla belled drugs added. These included 10 Ilmol/l phentola mine, an alpha blocker; 2 nrnol/l (+)-and (-)-propranolol, the stereoisomers of propranolol; I Ilmol/l and 50 nmol/l leI 89,406, a specific beta-one blocker; and I Ilmol/I and 25 nmol/l ICI 118,551, a specific beta-two blocker.
Propranolol and ICI 89,406 were kindly provided as gifts by Imperial Chemical Industries, Macclesfield, UK. leI 118,551 was purchased from Cambridge Research Biochemicals, Northwich, UK. The remaining drugs were all purchased from Sigma Chemical Co., Poole, UK.
Every fifth section was stained with haematoxylin and eosin instead of undergoing incubation, to demonstrate anatomical location.
RESULTS
There was a marked difference in density of labelling between sections incubated with ICYP alone and those incubated with a great excess of unlabelled propranolol. Particularly dense labelling was present on the optic nerve itself in the sections of anterior optic nerve ( Fig. 1 ) and optic nerve head (Fig. 2) . This tissue-specific binding using small concentrations of ligand which could be inhibited by a great excess of unlabelled beta blocker strongl y suggested that beta receptors were present in both anterior optic nerve and nerve head. No difference in bind ing occurred with the addition of 10 Ilmol/l phentolamine and 2 nmol/l (+ )-propranolol. However, there was reduced binding with 2 nmol/l (-)-propranolol which is the active stereoisomer of propranolol. These results pro vided further support for the presence of specific binding to beta receptors.
Radiolabelled beta blockers are known to bind non specifically to melanin. 1 9 Melanocytes have been reported in the region of the optic nerve head. 2 0 We identified mel anocytes surrounding the optic nerve and in the sclera in the sections of optic nerve head stained with haematoxylin and eosin (Fig. 2) . These correlated well with areas of non-specific binding on the autoradiographs. No melan ocytes were present in the optic nerve itself in either anterior optic nerve or optic nerve head.
Incubation with 1 Ilmol/l and 25 nmol/I ICI 118,551 (Figs. 3 and 5) resulted in a very marked reduction in bind ing. With 1 Ilmol/l ICI 89 406 (Fig. 4a) there was moder ate reduction in binding whereas with 50 nmol/l ICI 89,406 (Fig. 4b) there was a smaller alteration in binding. This suggests that the great majority of beta receptors in anterior optic nerve and optic nerve head are of the beta two subtype.
DISCUSSION
These experiments clearly show that beta receptors are present in anterior optic nerve and optic nerve head. Furthermore, the great majority of receptors are of the beta-two subtype. The resolution of the technique was insufficient to localise beta receptors to particular struc tures in the optic nerve head. The relatively high specific activity of iodine-125 produced uniform fogging of the film over the entire optic nerve. Furthermore the anatom ical register of the film with the slides was lost when the film was removed for development. Beta receptors could be present either on blood vessels or on glial cells. Beta receptors have, as stated above, already been identified on retinal vessels in both animals 10 and humans. II The majority of these are of the beta-two subtype. Moreover they have been localised to blood vessels elsewhere in the body as, for example, in the 2 1
• 22 heart, internal mammary artery and saphenous veIn. These are also mainly of the beta-two SUbtype. They have also been identified elsewhere in the central nervous system on c�rebral microvessels. 2 3 Again the great majority of these are of the beta-two sUbtype. 2 4 These find ings support the suggestion that beta receptors are present on blood vessels in anterior optic nerve.
There is some support for the other possibility, that the receptors may be on glial cells. Studies on rat cerebral cor tex in vivo have shown that stimulation of cyclic AMP production by noradrenaline, which is mediated by beta receptors, can be inhibited by fiuorocitrate. 2 5 Fluorocitrate is a glial-selective metabolic inhibitor. These studies sug gest that the majority of beta receptors in rat cerebral cor- There was a very marked reduction in the binding of ICYP in sections incubated with both 1 J..l mol/l and 25 nmol/l ICI 118,551, a specific beta-two antagonist. There was a moderate reduction in binding in sections incubated with 1 J..l mol/l ICI 89,406, with a smaller change when the 50 nmol/l concentration was used. Other studies on beta receptors elsewhere in the eye have concluded that the beta-two receptor subtype predominates although beta-one receptors are also present in significant numbers.6 However ICI 89,406, although principally a beta-one antagonist, does have some beta-two antagonist activity as well. Pharmacological studies on ICI 89,406 have shown that its dissociation constants for beta-one and beta-two receptors are 1.4 x 10-9 and 3.8 x 10-7 respect ively.z6 At 1 J..l mol/l it would therefore be expected to have beta-two antagonist activity as well. Some of the reduction in binding of ICYP observed at this concentration may have been due to this rather than to beta-one antagonism. At 50 nmol/l much less beta-two antagonist activity was present and there was less change in binding. Further more, ICI 118,551 at the lower concentration of 25 nmolll almost completely abolished binding of ICYP. At this low concentration it has almost entirely beta-two antagonist activity?7 These findings strongly suggest that the great majority of beta receptors in anterior optic nerve are of the beta-two subtype.
Beta-two receptors are found in vascular beds such as skeletal muscle and stimulation of these results in vaso dilatation.
14 It is possible that the beta-two receptors found in anterior optic nerve are situated on blood vessels and are concerned with vasodilatation.
Recent experimental studies on the arterioles supplying the ciliary processes in rabbits have shown constriction of the arteriolar cuffs at the beginning of these vessels fol- lowing single-dose administration of timolol and betaxo-101.28 This constriction is maintained over 7 weeks with timolol but with betaxolol the constriction wanes over the same period. This may be related to the selective beta blocking activity of betaxolol. Betaxolol selectively blocks beta-one receptors whereas timolol, which is non selective, blocks both beta-one and beta-two receptors. The beta receptors in the ciliary processes are predom inantly of the beta-two subtype.s It is possible that the mainly beta-one antagonist activity of betaxolol is insuf ficient to produce prolonged beta-two blockade with con striction of the arteriolar cuff. Timolol, however, could have sufficient beta-two antagonist action to cause per sisting constriction of the arteriolar cuff.
If a similar process were to occur in posterior segment vasculature such focal vasoconstriction could affect the vessels supplying the optic disc and cause ischaemia of optic nerve fibres.
Visual function can be assessed by measurement of the differential light threshold. This was measured in glau coma suspects before and after single doses of various glaucoma medications. 2 9 Timolol, acetazolamide and pin dolol all produced a reduction in intraocular pressure. With acetazolamide the differential light threshold tended to improve, whereas with timolol it tended to deteriorate. From this it was suggested that timolol, a non-selective beta blocker with no intrinsic sympathomimetic activity, had, in addition to reducing intraocular pressure, caused an alteration in blood flow to the posterior segment. Pin dolol, although non-selective, is a beta blocker with intrin sic sympathomimetic activity which might be expected to exert at least a partial protective effect on posterior seg ment blood flow. There was no overall change in the dif ferential light threshold following pindolol administration.
Further support for the hypothesis that some beta block ers might alter posterior segment blood flow is provided by a clinical study which has shown that patients with glaucoma treated with pindolol for 6 months demon strated a slight improvement in their visual fields com pared with a similar group treated with timolol who showed a slight deterioration?O A much longer prospec tive clinical study of a large group of ocular hypertensives involved random allocation of half the group to timolol treatment for up to 6 years.3! The other half were not treated. Although timolol successfully and consistently reduced the intraocular pressure in the treated group there was no significant difference in the average time to the development of glaucomatous changes compared with the untreated group. This is consistent with timolol altering posterior segment blood flow in addition to reducing intra ocular pressure.
A recent clinical study has shown that treatment of patients with established glaucoma with the selective beta blocker betaxolol over an 18-month period resulted in bet ter survival and improvement of the visual field than in a similar group treated with timolo1.3 2 The presence of almost entirely beta-two receptors in the vessels of the optic nerve head combined with these findings suggests that the use of a selective beta-one blocker such as betaxo-101 may be preferable to a non-selective beta blocker in the treatment of glaucoma.
